recombinant coagulation factor viii

Recombinant coagulation factor VIII is a genetically engineered protein used to treat and prevent bleeding episodes in individuals with hemophilia A and other conditions associated with low or deficient endogenous Factor VIII. It is produced using Chinese Hamster Ovary (CHO) cells that express the human Factor VIII gene, resulting in a glycosylated protein structurally and functionally similar to natural human Factor VIII. The drug acts as a replacement therapy by supplementing or restoring the missing clotting activity of endogenous Factor VIII, thereby enabling normal blood coagulation. Recombinant preparations are preferred over plasma-derived products due to reduced risk of blood-borne pathogen transmission. Some formulations have been modified for increased stability or extended half-life. Primary indications include treatment and prophylaxis of bleeding in hemophilia A; some products may also be used for von Willebrand disease[1][2][3][4][5].

Brand names

AdvateAdynovateHelixateKogenateKovaltryNovoeightRecombinateAfstyla

Other names

Factor VIII (recombinant)Coagulation factor VIII, human recombinantProcoagulant component (recombinant)Antihemophilic factor (recombinant)AHF (recombinant)